The preliminary therapy with decreased nerve degeneration and glial stimulation, and cytokine production, including IFN-, IL-17, IL-17A, TNF-, IL-1, and chemokines (MCP-1 and MIP-1)
generally avoided Concurrent use with other potent neuroactive compounds: manage carefully Recommended precautions Always begin under physician supervision with a full medical history review Start at the lowest effective dose and titrate slowly Use cycling protocols avoid indefinite continuous use Monitor for neurological overstimulation symptoms Regular follow-up consultations during active protocols Who may be a candidate for Dihexa therapy
It combines in one single product Reduced Glutathione and Quercetin at the maximum allowed daily intake, Naringenin, Selenium and a mix of natural ingredients with antioxidant action
As we age, NAD+ levels naturally decline, leading to fatigue, cognitive decline, and slower recovery